

1 August 2008

ReSearch Pharmaceutical Services, Inc.

Notice of Annual Meeting

ReSearch Pharmaceutical Services, Inc., a leading provider of clinical development outsourcing solutions to the biopharmaceutical industry, announces that notice of our 2008 annual meeting and proxy statement ("Proxy Statement") has today been mailed to our stockholders and warrant holders. The annual meeting is to be held at 9.00 a.m. on August 20, 2008 at RPS' office at 520 Virginia Drive, Fort Washington, Pennsylvania, 19034 ("Annual Meeting").

The Annual Meeting will, amongst other things, seek stockholders' approval for the cancellation of our common stock from trading on AIM and warrant holders' approval for the cancellation of our warrants from trading on AIM in anticipation of obtaining a listing on a United States securities exchange or electronic quotation medium.

Subject to obtaining our stockholders' and warrant holders' approval at the Annual Meeting, we intend to cancel the common stock and warrants from trading on AIM on September 1, 2008. We may choose to delay cancelling our common stock and warrants from trading on AIM, and if we do not cancel our common stock and warrants from trading on AIM on September 1, 2008, we will request an extension of the date of cancellation from AIM and publicly announce the new date of cancellation at least 10 business days prior to the new intended date of cancellation. In any event, we will not effect the cancellation of our common stock and warrants from trading on AIM on a date later than December 31, 2008 without obtaining an additional approval from our stockholders and warrant holders. We reserve the right to forego cancelling our common stock and warrants from trading on AIM if our Board of Directors determines that remaining admitted to trading on AIM is in the best interests of our stockholders and warrant holders.

In the event that the warrant holders do not approve the cancellation of the warrants from trading on AIM but the stockholders do approve the cancellation of the common stock from trading on AIM, our nominated adviser has indicated that it will resign as of the date our common stock is cancelled from trading on AIM. Thereafter, trading of our warrants on AIM will be suspended, and if we do not appoint another nominated advisor within one month after the suspension of our warrants from trading on AIM (which appointment of a new nominated advisor we believe is unlikely), the admission of our warrants to trading on AIM will be cancelled.

Additional information regarding the proposed cancellation of our stock and warrants from trading on AIM can be found in the Proxy Statement. This announcement is a summary of the information contained in the Proxy Statement and as such should be read in conjunction with the full text of the Proxy Statement.

The Proxy Statement is being filed with the United States Securities and Exchange Commission ("SEC") and is being mailed to our stockholders and warrant holders today. The Proxy Statement is publicly available on the SEC's website (www.sec.gov).

Copies of the Proxy Statement will also be available on the Company's website, www.rpsweb.com.

THIS ANNOUNCEMENT IS NOT "SOLICITING MATERIAL," IS NOT DEEMED "FILED" WITH THE SEC AND IS NOT TO BE INCORPORATED BY REFERENCE IN ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, WHETHER MADE BEFORE OR AFTER THE DATE HEREOF AND IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE IN ANY SUCH FILING.

For further information please contact:

ReSearch Pharmaceutical Services, Inc.: +1 215 540 0700
Daniel M. Perlman, Chairman & Chief Executive Officer
Steven Bell, Chief Financial Officer

Nominated Adviser and UK Broker: +44 20 7012 2100
Arbuthnot Securities Limited
James Steel/Richard Tulloch